Repligen (RGEN)
(Delayed Data from NSDQ)
$161.67 USD
-4.00 (-2.41%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $161.66 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RGEN 161.67 -4.00(-2.41%)
Will RGEN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RGEN
Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates
Repligen (RGEN) Q2 Earnings Meet Estimates
RGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?
Other News for RGEN
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Repligen’s Buy Rating Affirmed Amid Strong Growth and Strategic Initiatives
Buy Rating Reaffirmed for Repligen Amid Strong Growth Prospects and Market Resilience
Repligen (RGEN) Shares Cross Above 200 DMA